Cidara Therapeutics announced two poster presentations highlighting data on CD388 at the 34th European Society of Clinical Microbiology and Infectious Diseases conference, being held April 27-30, 2024 in Barcelona, Spain. The first presentation highlights data from the Phase 2a study of CD388, showing the DFC was well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challenged with influenza. The second presentation highlights data from a Phase 1 single ascending dose study of CD388 which showed the drug has an extended half-life of 6-8 weeks. These data underscore the potential of CD388 to provide patients with seasonal influenza prevention.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics Refocuses Strategy with Asset Sale
- Cidara Therapeutics: Strategic Partnerships and Governance Changes
- Cidara Therapeutics reacquires rights to CD388 from Johnson & Johnson for $85M
- Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
- Cidara Therapeutics divests rezafungin to Mundipharma
